Curaleaf Holdings, Inc. (OTCQX: CURLF) (CSE:CURA) completed its agreement to acquire a 55% stake in Four 20 Pharma GmbH, a fully EU-GMP & GDP licensed German producer and distributor of medical cannabis.

Boris Jordan, executive chairman of Curaleaf, stated, "We are pleased to complete the transaction with Four 20 Pharma and I am personally thrilled to welcome Torsten and Thomas to the Curaleaf family. Our early focus on Europe has given Curaleaf a formidable strategic asset and strong foundation in one of the industry's critical global markets. Curaleaf is the only U.S. MSO uniquely positioned to capitalize on the opportunity."

With the close of the transaction, Curaleaf has solidified a strategic pathway to acquire complete …

Full story available on Benzinga.com